Interaction between Mean Arterial Pressure and HbA1c in Prediction of Cardiovascular Disease Hospitalisation: A Population-Based Case-Control Study by Yu, D et al.
Research Article
Interaction between Mean Arterial Pressure and
HbA1c in Prediction of Cardiovascular Disease Hospitalisation:
A Population-Based Case-Control Study
Dahai Yu,1,2 Zhanzheng Zhao,1 and David Simmons3
1Department of Nephrology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China
2Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health Sciences, Keele University,
Keele ST5 5BG, UK
3Western Sydney University, Campbelltown, Sydney, NSW 2751, Australia
Correspondence should be addressed to Zhanzheng Zhao; zhanzhengzhao@zzu.edu.cn
and David Simmons; dsworkster@gmail.com
Received 13 January 2016; Revised 10 April 2016; Accepted 22 May 2016
Academic Editor: Kim Connelly
Copyright © 2016 Dahai Yu et al.This is an open access article distributed under the Creative CommonsAttribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To explore the relationship between mean arterial pressure (MAP), HbA1c, and cardiovascular (CV) hospitalisation risk
in type 2 diabetes. Design. Population-based case-control study. Settings. Primary and secondary care level in Cambridgeshire,
United Kingdom. Participants. 588 patients with type 2 diabetes from 18 English general practices recording a CV hospitalisation
in 2009–2011 were included. Risk-set sampling was used to select 2920 gender, age, and practice matched control type 2 diabetes
patients.Main Outcome Measure. Conditional logistic regression was used to explore further dose-response relationships between
MAP, HbA1c, and CV hospitalisation risk. Results.The relationship betweenMAP and CV hospitalisation was nonlinear (𝑃 < 0.001
for linearity test). The MAP associated with the lowest CV hospitalisation risk was 97 (95% CI: 93–101)mmHg. An interaction
between MAP and HbA1c for increased risk of cardiovascular hospitalisation was observed among those with HbA1c < 7%
(53mmol/mol) and MAP < 97mmHg. Conclusions. In type 2 diabetes, MAP is a good predictor of CV hospitalisation risk. CV
hospitalisation is lowest with a MAP between 93 and 101mmHg. CV hospitalisation was particularly high among those with both
a low MAP and a lower HbA1c.
1. Introduction
Blood pressure is a major contributory factor in cardiovascu-
lar disease (CVD) [1], with systolic blood pressure (SBP) cur-
rently considered the best general populationCVD risk factor
[2]. Type 2 diabetes is another major risk factor for CVD
[3] and its coexistence with hypertension increases CVD
risk further, although this additional risk is not observed
in all studies [4]. It was estimated that in the United States
30% of inpatient cost (around 22,254 million US dollars)
was due to CVD hospitalisation among people with type 2
diabetes in 2012 [5]. An even greater diabetes-attributable
hospitalisation cost of 46.5% was found in a major hospital
in Cambridgeshire, England [6]. A paradoxical finding is
that the well-known relationship between CVD and SBP in
the general population was insignificant in a meta-analysis
using data from people with diabetes [4]. Greater use of
antihypertensive medicine and a higher prevalence of heart
failure than people without diabetes have been proposed as
possible reasons for this paradox [7, 8].
Mean arterial pressure (MAP) reflects both peripheral
resistance and cardiac output. Recently, in the ADVANCE
study [9], a trial among type 2 diabetes patients, MAP
correlated withmajor CVD events: with a 13% increase in risk
per 13mmHg increase in MAP. If MAP is a marker for CVD
risk among type 2 diabetes patients, it should be associated
with greater CVD hospitalisation. However, the association
between MAP and hospitalisation in type 2 diabetes has not
been investigated, and a dose-response relationship between
CVD hospitalisation and MAP may exist. Moreover, blood
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pressure and CVD are influenced by long term glycaemic
control [10], usually assessed using HbA1c, which also has an
association with hospitalisation risk [11].
We therefore hypothesized thatMAPwould predict CVD
hospitalisation in type 2 diabetes in a nonlinear relationship,
with an interaction between HbA1c and MAP. We also
investigated whether a threshold exists below whichMAP no
longer predicts CVD hospital admission.
2. Methods
2.1. Settings. Secondary Uses Service (SUS) hospitalisation
data up to 2010-2011 was linked with data from all patients
with type 2 diabetes from 18 volunteer Cambridgeshire
general practices in 2008/9 as previously described [11].
Only practices using the EMIS (Egton Medical Information
Systems) GP electronic records were involved as the system
allowed extraction of a predefined dataset. SUS data includes
all NHS and private hospital admissions from both within
and outside Cambridgeshire. All analyses were conducted
on anonymised datasets and the work was approved by the
Cambridgeshire Research Ethics Committee [11].
Type 2 diabetes was based upon GP recorded diagnosis,
the ICD coding in the SUS dataset, current age, and the
youngest recorded age at diagnosis (where both type 2 and
type 1 diabetes were defined in different datasets). Hospital
ICD coding (E10–E14) occurred for all patients with diabetes.
Data from general practice included demographics, body
mass index (BMI), some medications, and metabolic vari-
ables including lipid profiles and HbA1c. SBP and DBP were
measured over the baseline time period: 89.3% people within
and 10.7% beyond the first 12 months. All blood pressure was
taken before April 1, 2009, with the most recent (at least 50
days before the first admission) used in the analysis.MAPwas
calculated as [(2 × DBP) + SBP]/3.
Time since diabetes registration duration usually reflect-
ed the diabetes duration. Aspirin and lipid-lowering, but not
diabetes, therapy were recorded along with previous CVD
history.
2.2. Study Participants. Patients with a first recorded inpa-
tient diagnosis of CVD as the primary code (ICD-10: I20–
I25, I60–I69, and I73 in first ICD field) for the hospital
admission over the 2-year time period (1April 2009–31March
2011) were defined as cases. The first hospitalisation date
was taken as the index date for cases. Randomly sampled
matched (by age, gender, and practice) controls were selected
(1 : 5 case : control) using risk-set sampling [12]. Controlswere
assigned an index date identical to that of corresponding
cases. Eligible controls had noCVDhospitalisation by the age
of the matched cases.
2.3. Statistical Analysis. Conditional logistic regression was
used for categorical variables comparisons and mixed effect
models for continuous variables after age adjustment. Con-
ditional logistic regression was used to compute odds ratios
for CVD hospitalisation by mean arterial pressure levels [13].
The odds ratios estimated the incidence rate ratios as risk-set
sampling of controls was used [13].
Analyses were adjusted for BMI, triglyceride, total choles-
terol, low density lipoprotein, high density lipoprotein, dura-
tion of diabetes registration in GP practices, lipid-lowering
and aspirin treatment, and prevalent recorded history of
CVD/cerebrovascular disease.
The interaction between HbA1c and MAP in predicting
hospital admission was analysed by dichotomising the rela-
tionship between two levels of HbA1c, set at the ADA usual
target for HbA1c (HbA1c < 7% (53mmol/mol) and HbA1c ≥
7% (53mmol/mol)).
The relationships between MAP and hospital admissions
were estimated using a linear model, natural cubic spline
model with 3 equally spaced knots determined from the
levels of MAP, and quadratic spline model, respectively. The
natural cubic splinemodelwas chosen as the best fitmodel for
the relationship curve by its minimum Akaike Information
Criteria (AIC) compared with linear model or quadratic
spline model [14]. The natural cubic spline models for the
overall dataset were repeated using other potential knots,
chosen to lie within the range for minimum to maximum
measure of MAP (as a sensitivity analysis). The linearity
of the relationship was tested using the linear test in the
natural cubic spline model. The breakpoint test was carried
out to target the potential thresholds (P
5
to P
95
of MAP
measures) by incorporating the piecewise term into the cubic
spline model [15]. The threshold with significant break in the
regression coefficients and achieving the minimum AIC was
chosen as the final threshold. The 95% confidence interval of
the threshold was obtained from 1000 bootstrap samples.
The model discrimination was estimated by C-statistics
(equal to the area under the Receiver Operating Character-
istic (ROC) curves) from multilevel mixed effects logistic
regression (two-level model), within which the matched
risk-set was fixed. Mean variance inflation factor (VIF) was
evaluated to avoid the impacts of multicollinearity between
different variables in the model.
Two sensitivity analyses were undertaken firstly analysing
the MAP measurement data rich range (covering > 95%
people): 60–120mmHg, and secondly limiting the period to
CVDhospitalisation after the first threemonths following the
start of follow-up.
All analyses were performed with STATA (STATA/SE 11.0
StataCorp, Texas). All 𝑃 values were calculated using two-
tailed tests and 𝑃 < 0.05 was taken as significant.
3. Results
The 588 cases and 2920 population controls are described in
Table 1, which shows the high rate of previously diagnosed
coronary heart disease (66.8% versus 35.6% of controls) and
higher BMI, SBP, DBP, HbA1c, low density lipoprotein, and
triglyceride in cases.The averageMAPwas 94.1±10.2mmHg
among cases and 91.3 ± 9.2mmHg among controls (𝑃 =
0.0130).
A nonlinear relationship between MAP and risk of
CVD hospital admission was found (Figure 1: linearity test:
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Table 1: Characteristics of patients with cardiovascular hospitalisation and matched controls.
Cases (𝑛 = 588) Controls (𝑛 = 2920) 𝑃 value
Systolic blood pressure, mmHg 135.1 ± 12.9 134.0 ± 11.1 0.0264
Diastolic blood pressure, mmHg 73.0 ± 10.1 72.0 ± 10.0 0.0368
Mean arterial pressure, mmHg 94.1 ± 10.2 91.3 ± 9.2 0.0130
Pulse pressure, mmHg 62.1 ± 12.1 61.0 ± 12.0 0.0165
Body mass index, kg/m2 30.4 ± 5.6 29.0 ± 5.8 <0.0001
HbA1c, mmol/mol (%) 62 (7.8) ± 18 (1.6) 57 (7.4) ± 14 (1.3) <0.0001
Total cholesterol, mmol/L 4.1 ± 1.0 4.2 ± 1.0 0.0270
Triglyceride, mmol/L 2.0 ± 1.0 1.7 ± 0.9 <0.0001
High density lipoprotein, mmol/L 1.1 ± 0.3 1.2 ± 0.4 0.0020
Low density lipoprotein, mmol/L 2.2 ± 0.8 2.4 ± 0.8 0.0060
Estimated glomerular filtration rate, mL/min/1.73m2 56.8 ± 18.9 56.6 ± 17.9 0.865
Current smoker/ex-smoker 66.9 65.8 0.623
Pulse pressure, mmHg 60.9 ± 14.9 61.9 ± 13.8 0.426
Coronary heart disease history, % 66.8 35.6 <0.0001
Cerebrovascular disease, % 16.8 14.4 0.1320
Lipid-lowering treatment, % 86.9 72.2 <0.0001
Aspirin treatment, % 66.9 53.7 <0.0001
𝑃 < 0.001), with the lowest risk of CVD hospitalisation with
MAP of 97 (95% CI: 93 to 101) mmHg. Increased hospitalisa-
tion occurred above and below this MAP threshold.
An interaction between MAP and HbA1c in predicting
the risk of CVD hospitalisation was observed: below the
MAP threshold, people with a low HbA1c (HbA1c < 7%
(53mmol/mol)) were more likely to have a cardiovascular
hospitalisation compared with those with a high HbA1c
(HbA1c ≥ 7% (53mmol/mol)). Above the MAP threshold,
the risk of cardiovascular hospitalisation increased with each
increment in MAP among people with a high, but not a low,
HbA1c.
The nonlinear association was also found within the
data rich range (60–120mmHg for MAP) (Figure 2) with
significantly higher CVD hospitalisation below/above the
97mmHg MAP threshold. The interaction between MAP
and HbA1c in predicting CVD hospitalisation was similar to
the interaction observed in the full data range. Qualitatively
similar findings were found for the association between
MAP and CVD hospitalisation after excluding cases whose
hospital admissions were recorded in the first 3 months
of follow-up (see Supplementary Figure 1 and Supplemen-
tary Figure 2 in Supplementary Material available online
at http://dx.doi.org/10.1155/2016/8714745). In another sensi-
tivity analysis restricting MAP to 80–120mmHg, a similar
association was revealed (Supplementary Figure 3).
Finally, we estimated that any unmeasured confounder
that was 1.5-fold as frequent among those with MAP <
97mmHg as it was among people with MAP outside this
range would need to decrease the risk of cardiovascular
hospitalisation by a factor of ≥20 to fully explain the results, if
no increased risk actually existed (Supplementary Figure 4).
4. Discussion
We have shown, to our knowledge for the first time, that
MAP and CVD hospitalisation show a nonlinear relationship
among patients with type 2 diabetes within a U shaped
relationship and a threshold of 97mmHg. The MAP inter-
action with HbA1c was particularly of interest, with a lower
HbA1c below the MAP threshold and higher HbA1c above
the MAP threshold being associated with the greater risk of
cardiovascular hospitalisation.
The association between an elevated MAP and both
increased CVD and total mortality [2] in the general popu-
lation is well established. For example, in the Framingham
Heart Study, 14mmHg increase of MAP was associated with
a 35% elevation in CVD risk [16]. Our data are in agreement
with these previous reports and show that arterial resistance
(represented approximately by MAP) also has an adverse
effect on the subsequent risk of CVD in those with type 2
diabetes. A positive association between future CVD risk and
MAP in patients with type 2 diabetes was shown by Kodama
et al. in a meta-analysis [4] with a 9% increased CVD risk
for every +10mmHg increment of MAP. This supports MAP
as a good prognostic predictor of CVD risk in people with
type 2 diabetes. MAP was suggested to be a strong predictor
of CVD even when SBPwas controlled to normal, supporting
our view that MAP is an independent risk factor rather than
a proxy for SBP or DBP.
In the Physicians’ Health Study [17], which investigated
22071US male physicians aged 40 to 84 years, with a
follow-up of 10.8 years, a nonlinear association was found
between MAP and risk of CVD. The lowest risk of CVD
was found at 93–97mmHg of MAP among men aged <60
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Figure 1: Relationship between mean arterial pressure and cardiovascular hospital admission: analysis in full data range. Adjusted for
prevalent recorded history of cardiovascular/cerebrovascular disease, duration of diabetes registration in GP practices, body mass index,
triglyceride, total cholesterol, low density lipoprotein, high density lipoprotein, estimated glomerular filtration rate, smoking status, lipid-
lowering treatment, aspirin treatment, and pulse pressure. The thick dash-dot line indicates the incidence rate ratio and the thin dash line
indicates the 95% confidence interval. The rag plot (bars on the 𝑥-axis) presents the mean arterial pressure distribution.
years, and increasedCVD riskwas identified below and above
the threshold. However, to our knowledge, the relationship
between MAP and hospitalisation, especially CVD hospi-
talisation, has not been investigated before and might be
an indicator for healthcare for people with type 2 diabetes
[5, 6]. Ours are consistent with previous findings and provide
further evidence of a nonlinear association betweenMAPand
CVD hospitalisation. We have also identified that there is a
threshold with the lowest risk of CVD hospitalisation present
at 93–101mmHg of MAP.
Our finding of an interaction between MAP and HbA1c
suggests that patients with a low MAP should not have a
lower target HbA1c.This is in keeping with the generic guide-
lines around setting a higher HbA1c target among patients
with CVD and particularly followed the findings from the
Veterans [18] study that lower HbA1c among patients with
prevalent CVD is associated with greater adverse outcomes
including death. We tested whether a low HbA1c, among
patients with a MAP below threshold, would be amenable to
new post hoc studies using existing RCT data.
MAP is thought to act as a surrogate marker for vascular
stiffness resulting from a loss of vascular elasticity [19]. Such
loss of elasticity arises from alterations in collagen and elastin
structure and function which may arise from the increased
Journal of Diabetes Research 5
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Figure 2: Relationship between mean arterial pressure and cardiovascular hospital admission: analysis in data rich range. Adjusted for
prevalent recorded history of cardiovascular/cerebrovascular disease, duration of diabetes registration in GP practices, body mass index,
triglyceride, total cholesterol, low density lipoprotein, high density lipoprotein, estimated glomerular filtration rate, smoking status, lipid-
lowering treatment, aspirin treatment, and pulse pressure. The thick dash-dot line indicates the incidence rate ratio and the thin dash line
indicates the 95% confidence interval. The rag plot (bars on the 𝑥-axis) presents the mean arterial pressure distribution.
oxidative stress, carbonyl stress, and advanced glycation
end products associated with the relative hyperglycaemia of
diabetes and prediabetes [19]. On the other hand, vascular
stiffness also increases with advancing age, leading to coro-
nary heart disease.We speculate that this increase in vascular
stiffness could explain the abnormal MAP in type 2 diabetes
patients and their excess CVD risks [20].
How MAP or arterial stiffness can be reduced is uncer-
tain: current antihypertensive treatment reduces both SBP
and DBP and MAP might not change linearly. However,
if a high or low MAP is identified (e.g., ≤90mmHg or
≥100mmHg MAP to use rounded numbers and address any
accuracy issues), lifestyle factors (e.g., diet, physical activity,
and smoking) could be discussed in the context of a new
finding and therapy could be intensified. Whether such
a strategy is beneficial warrants further study, possibly a
randomised controlled trial.
Our study has some limitations including the lack of
detailed antihypertensive medicine information. However
antihypertensive medicine therapy might not distort the
relationship between MAP and risk of CVD hospitalisation
identified in this study as such treatment is the “norm”
for the majority of type 2 diabetes patients. This is likely
to be reflected by the normal mean BP observed in both
6 Journal of Diabetes Research
cases and controls in the present analysis. Blood pressure
(and therefore MAP) was not measured with epidemiologi-
cally robust methods but reflected “real life” blood pressure
measurements. This would have likely reduced the chance
of finding differences in view of the increased variance
unless there was a systematic bias. On the other hand, such
routine medical record data might be more readily available
for individual risk prediction than other measures. Reverse
causality (i.e., the index blood pressure was measured after
the episode of illness that led to the hospital admission) is
unlikely to have contributed to our findings as there was at
least 50 days between the index blood pressure and hospital
admission. Naturally, those with eg cardiomyopathy would
be expected to be included in the low MAP group and
have an increased chance of hospitalisation. The relationship
between MAP and CVD hospitalisation might be greater in
populations where CVD risk has not been reduced through
high lipid-lowering therapy uptake. Indeed, the relatively
limited sample size and the potential for our adjustments to
be insufficient to address any unknown factors support the
testing of these associations and the threshold in a prospective
study of longer duration. Although the multicollinearity
between MAP and other covariables was not identified in
our study, further validation with external data with a large
sample size is needed. Further limitations are that only a
proportion of GPs in the area provided their data and these
were restricted to EMIS users. We have no reason to believe
that diabetes care among EMIS users contributing data was
any better or worse than otherGPs, but this is a limitation. GP
diabetes coding could be a limitation [21], but the approach
has been used previously and is considered valid.
In summary, nonlinear relationship exists between MAP
and cardiovascular hospital admission in type 2 diabetes
patients. The MAP threshold for the lowest hospital admis-
sion was 97 (95% CI: 93, 101)mmHg. In people with type
2 diabetes, the MAP interacted with HbA1c in defining the
risk of cardiovascular hospitalisation. MAPmight be a useful
measure to consider risk in clinical practice.
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